I defy anyone to explain the over/under 65 situation. I’m not asking for guesses! And I’m not expecting answers because if MSB can’t answer (and they haven’t) then it’s not possible that anyone on HC can.
Think about this though:
The COVID-19 trial has kicked up differing results relative to AGE. Now think about the trial for AGVHD with the kids!!!
If differing results are found with the same cells on people of different ages then the FDA has made a fantastic decision by knocking back MSB and saving the kids from who knows what the cells would do to them!!
Now go back and read the questions at the ODAC meeting and look at the answers with this in mind.
The FDA will be found to have asked MSB to prove and explain the mechanisms of the trial successes and MSB could not do that! As such the FDA did not give approval and was legitimised when weeks later another trial showed that different results were had by stem cells with different age groups. The FDA saved the kids!!!!
Ann: Mesoblast Q3 Financial Results Webcast, page-165
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.38 |
Change
-0.010(0.72%) |
Mkt cap ! $1.581B | |||
| Open | High | Low | Value | Volume |
| $1.40 | $1.42 | $1.38 | $3.405M | 2.445M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 27 | 110575 | $1.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.38 | 14000 | 1 |
View Market Depth
| Last trade - 15.25pm 10/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |